Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with 90Y-biotin?

Chiara Grana, Mirco Bartolomei, Daria Handkiewicz, Paola Rocca, Lisa Bodei, Nicoletta Colombo, Marco Chinol, Costantino Mangioni, Fabio Malavasi, Giovanni Paganelli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives. Despite recent advances in the management of ovarian cancer, this tumor remains the leading cause of death among gynecologic malignancies. Moreover, advanced ovarian carcinoma has a poor prognosis, thus requiring new therapeutic modalities. Previous studies have indicated a survival advantage for ovarian cancer patients (pts) treated with radioimmunotherapy (RIT). Pre-targeting RIT, based on the avidin-biotin system, has been the objective of previous studies performed by our group. Patients and methods. In the present study, the therapeutic efficacy and toxicity of RIT in 38 advanced ovarian cancer patients have been retrospectively evaluated. RIT was performed according to the following three-step protocol: biotinylated monoclonal antibodies (MoAb) and avidin were intraperitoneally (ip) injected (1st and 2nd step), and 12-18 h later 90Y-labeled biotin either iv or ip was injected as 3rd step. Sixteen out of 38 patients were treated by intraperitoneal injection only, whereas other 22 pts received the combined treatment (ip + iv); the dose range was 10-100 mCi of 90Y-biotin. Results. Both of the two therapy regimens were well tolerated; no acute side effects were observed. Two patients (5%) showed temporary hematological grade III-IV toxicity. As regards to the therapeutic efficacy, in the ip group we observed 6% of objective tumor reduction, stabilization in 31% of pts, and progression in 50%. In the group of combined treatment, 9% of patients achieved objective responses, 32% showed stable disease, and 41% had a progression. Conclusions. These data show the excellent tolerability (maximum tolerated dose (MTD) has not been determined yet) and the potential therapeutic role of RIT in advanced ovarian cancer. Patients with minimal residual disease would probably take the best advantages of RIT with 90Y-biotin (electrons). These data warrant further prospective studies.

Original languageEnglish
Pages (from-to)691-698
Number of pages8
JournalGynecologic Oncology
Volume93
Issue number3
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Radioimmunotherapy
Biotin
Ovarian Neoplasms
Avidin
Therapeutics
Neoplasms
Maximum Tolerated Dose
Residual Neoplasm
Intraperitoneal Injections
Cause of Death
Monoclonal Antibodies
Prospective Studies
Electrons
Carcinoma

Keywords

  • Avidin-biotin
  • Ovarian cancer
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Radioimmunotherapy in advanced ovarian cancer : Is there a role for pre-targeting with 90Y-biotin? / Grana, Chiara; Bartolomei, Mirco; Handkiewicz, Daria; Rocca, Paola; Bodei, Lisa; Colombo, Nicoletta; Chinol, Marco; Mangioni, Costantino; Malavasi, Fabio; Paganelli, Giovanni.

In: Gynecologic Oncology, Vol. 93, No. 3, 06.2004, p. 691-698.

Research output: Contribution to journalArticle

Grana, Chiara ; Bartolomei, Mirco ; Handkiewicz, Daria ; Rocca, Paola ; Bodei, Lisa ; Colombo, Nicoletta ; Chinol, Marco ; Mangioni, Costantino ; Malavasi, Fabio ; Paganelli, Giovanni. / Radioimmunotherapy in advanced ovarian cancer : Is there a role for pre-targeting with 90Y-biotin?. In: Gynecologic Oncology. 2004 ; Vol. 93, No. 3. pp. 691-698.
@article{ee3d180b0c9648559abff7d07aeaaf62,
title = "Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with 90Y-biotin?",
abstract = "Objectives. Despite recent advances in the management of ovarian cancer, this tumor remains the leading cause of death among gynecologic malignancies. Moreover, advanced ovarian carcinoma has a poor prognosis, thus requiring new therapeutic modalities. Previous studies have indicated a survival advantage for ovarian cancer patients (pts) treated with radioimmunotherapy (RIT). Pre-targeting RIT, based on the avidin-biotin system, has been the objective of previous studies performed by our group. Patients and methods. In the present study, the therapeutic efficacy and toxicity of RIT in 38 advanced ovarian cancer patients have been retrospectively evaluated. RIT was performed according to the following three-step protocol: biotinylated monoclonal antibodies (MoAb) and avidin were intraperitoneally (ip) injected (1st and 2nd step), and 12-18 h later 90Y-labeled biotin either iv or ip was injected as 3rd step. Sixteen out of 38 patients were treated by intraperitoneal injection only, whereas other 22 pts received the combined treatment (ip + iv); the dose range was 10-100 mCi of 90Y-biotin. Results. Both of the two therapy regimens were well tolerated; no acute side effects were observed. Two patients (5{\%}) showed temporary hematological grade III-IV toxicity. As regards to the therapeutic efficacy, in the ip group we observed 6{\%} of objective tumor reduction, stabilization in 31{\%} of pts, and progression in 50{\%}. In the group of combined treatment, 9{\%} of patients achieved objective responses, 32{\%} showed stable disease, and 41{\%} had a progression. Conclusions. These data show the excellent tolerability (maximum tolerated dose (MTD) has not been determined yet) and the potential therapeutic role of RIT in advanced ovarian cancer. Patients with minimal residual disease would probably take the best advantages of RIT with 90Y-biotin (electrons). These data warrant further prospective studies.",
keywords = "Avidin-biotin, Ovarian cancer, Radioimmunotherapy",
author = "Chiara Grana and Mirco Bartolomei and Daria Handkiewicz and Paola Rocca and Lisa Bodei and Nicoletta Colombo and Marco Chinol and Costantino Mangioni and Fabio Malavasi and Giovanni Paganelli",
year = "2004",
month = "6",
doi = "10.1016/j.ygyno.2004.02.017",
language = "English",
volume = "93",
pages = "691--698",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Radioimmunotherapy in advanced ovarian cancer

T2 - Is there a role for pre-targeting with 90Y-biotin?

AU - Grana, Chiara

AU - Bartolomei, Mirco

AU - Handkiewicz, Daria

AU - Rocca, Paola

AU - Bodei, Lisa

AU - Colombo, Nicoletta

AU - Chinol, Marco

AU - Mangioni, Costantino

AU - Malavasi, Fabio

AU - Paganelli, Giovanni

PY - 2004/6

Y1 - 2004/6

N2 - Objectives. Despite recent advances in the management of ovarian cancer, this tumor remains the leading cause of death among gynecologic malignancies. Moreover, advanced ovarian carcinoma has a poor prognosis, thus requiring new therapeutic modalities. Previous studies have indicated a survival advantage for ovarian cancer patients (pts) treated with radioimmunotherapy (RIT). Pre-targeting RIT, based on the avidin-biotin system, has been the objective of previous studies performed by our group. Patients and methods. In the present study, the therapeutic efficacy and toxicity of RIT in 38 advanced ovarian cancer patients have been retrospectively evaluated. RIT was performed according to the following three-step protocol: biotinylated monoclonal antibodies (MoAb) and avidin were intraperitoneally (ip) injected (1st and 2nd step), and 12-18 h later 90Y-labeled biotin either iv or ip was injected as 3rd step. Sixteen out of 38 patients were treated by intraperitoneal injection only, whereas other 22 pts received the combined treatment (ip + iv); the dose range was 10-100 mCi of 90Y-biotin. Results. Both of the two therapy regimens were well tolerated; no acute side effects were observed. Two patients (5%) showed temporary hematological grade III-IV toxicity. As regards to the therapeutic efficacy, in the ip group we observed 6% of objective tumor reduction, stabilization in 31% of pts, and progression in 50%. In the group of combined treatment, 9% of patients achieved objective responses, 32% showed stable disease, and 41% had a progression. Conclusions. These data show the excellent tolerability (maximum tolerated dose (MTD) has not been determined yet) and the potential therapeutic role of RIT in advanced ovarian cancer. Patients with minimal residual disease would probably take the best advantages of RIT with 90Y-biotin (electrons). These data warrant further prospective studies.

AB - Objectives. Despite recent advances in the management of ovarian cancer, this tumor remains the leading cause of death among gynecologic malignancies. Moreover, advanced ovarian carcinoma has a poor prognosis, thus requiring new therapeutic modalities. Previous studies have indicated a survival advantage for ovarian cancer patients (pts) treated with radioimmunotherapy (RIT). Pre-targeting RIT, based on the avidin-biotin system, has been the objective of previous studies performed by our group. Patients and methods. In the present study, the therapeutic efficacy and toxicity of RIT in 38 advanced ovarian cancer patients have been retrospectively evaluated. RIT was performed according to the following three-step protocol: biotinylated monoclonal antibodies (MoAb) and avidin were intraperitoneally (ip) injected (1st and 2nd step), and 12-18 h later 90Y-labeled biotin either iv or ip was injected as 3rd step. Sixteen out of 38 patients were treated by intraperitoneal injection only, whereas other 22 pts received the combined treatment (ip + iv); the dose range was 10-100 mCi of 90Y-biotin. Results. Both of the two therapy regimens were well tolerated; no acute side effects were observed. Two patients (5%) showed temporary hematological grade III-IV toxicity. As regards to the therapeutic efficacy, in the ip group we observed 6% of objective tumor reduction, stabilization in 31% of pts, and progression in 50%. In the group of combined treatment, 9% of patients achieved objective responses, 32% showed stable disease, and 41% had a progression. Conclusions. These data show the excellent tolerability (maximum tolerated dose (MTD) has not been determined yet) and the potential therapeutic role of RIT in advanced ovarian cancer. Patients with minimal residual disease would probably take the best advantages of RIT with 90Y-biotin (electrons). These data warrant further prospective studies.

KW - Avidin-biotin

KW - Ovarian cancer

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=2942637964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942637964&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.02.017

DO - 10.1016/j.ygyno.2004.02.017

M3 - Article

C2 - 15196866

AN - SCOPUS:2942637964

VL - 93

SP - 691

EP - 698

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -